Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Molecular targets for antiepileptic drug development.

Meldrum BS, Rogawski MA.

Neurotherapeutics. 2007 Jan;4(1):18-61. Review.

2.

Ion channels and epilepsy.

Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adín J.

Curr Pharm Des. 2005;11(15):1975-2003. Review.

PMID:
15974971
3.

Research advances in basic mechanisms of seizures and antiepileptic drug action.

Lasoń W, Chlebicka M, Rejdak K.

Pharmacol Rep. 2013;65(4):787-801. Review.

4.

Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy.

Cosford ND, Meinke PT, Stauderman KA, Hess SD.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):81-104. Review.

PMID:
12769636
5.

[Ion channels and epilepsy].

Armijo JA, de las Cuevas I, Adín J.

Rev Neurol. 2000 Jun;30 Suppl 1:S25-41. Review. Spanish.

PMID:
10904966
6.

Are alterations in transmitter receptor and ion channel expression responsible for epilepsies?

Powell KL, Lukasiuk K, O'Brien TJ, Pitkänen A.

Adv Exp Med Biol. 2014;813:211-29. doi: 10.1007/978-94-017-8914-1_17. Review.

PMID:
25012379
7.

HCN and KV7 (M-) channels as targets for epilepsy treatment.

Shah MM, Huang Z, Martinello K.

Neuropharmacology. 2013 Jun;69:75-81. doi: 10.1016/j.neuropharm.2012.03.005. Epub 2012 Mar 15. Review.

8.

Ion channels as important targets for antiepileptic drug design.

Yogeeswari P, Ragavendran JV, Thirumurugan R, Saxena A, Sriram D.

Curr Drug Targets. 2004 Oct;5(7):589-602. Review.

PMID:
15473249
9.

Ion channel defects in idiopathic epilepsies.

Lerche H, Weber YG, Jurkat-Rott K, Lehmann-Horn F.

Curr Pharm Des. 2005;11(21):2737-52. Review.

PMID:
16101452
10.

New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.

Rogawski MA, Bazil CW.

Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. Review.

11.

Plasticity of antiepileptic drug targets.

Beck H.

Epilepsia. 2007;48 Suppl 1:14-8. Review.

12.

Identification and preclinical testing of novel antiepileptic compounds.

Meldrum BS.

Epilepsia. 1997;38 Suppl 9:S7-15. Review.

13.

Neurophysiology of HCN channels: from cellular functions to multiple regulations.

He C, Chen F, Li B, Hu Z.

Prog Neurobiol. 2014 Jan;112:1-23. doi: 10.1016/j.pneurobio.2013.10.001. Epub 2013 Oct 29. Review.

PMID:
24184323
14.

HCN channelopathies: pathophysiology in genetic epilepsy and therapeutic implications.

Reid CA, Phillips AM, Petrou S.

Br J Pharmacol. 2012 Jan;165(1):49-56. doi: 10.1111/j.1476-5381.2011.01507.x. Review.

15.

Channelopathies as a genetic cause of epilepsy.

Mulley JC, Scheffer IE, Petrou S, Berkovic SF.

Curr Opin Neurol. 2003 Apr;16(2):171-6. Review.

PMID:
12644745
17.

New antiepileptic drugs: molecular targets.

Mula M.

Cent Nerv Syst Agents Med Chem. 2009 Jun;9(2):79-86. Review.

PMID:
20021341
18.

[Genetic approach to the pathogeneses of epilepsy].

Hirose S.

Rinsho Shinkeigaku. 2004 Nov;44(11):975-8. Review. Japanese.

PMID:
15651347
19.
20.

Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes.

Abdelsayed M, Sokolov S.

Channels (Austin). 2013 May-Jun;7(3):146-52. doi: 10.4161/chan.24380. Epub 2013 Mar 26. Review.

Supplemental Content

Support Center